welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million
Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
expertly curated content related to this topic
-
beating bowel cancerBowel Cancer Voices get involved in a wi...
-
gary mathiasCo-Founder and CEO, Thetis Pharmaceutica...
-
cats love peanut butterHi there! I’m Amy and I am a web desig...
-
Why I Struggle to Introduce My Illness to OthersTo be completely honest, I have no idea ...
-
feeling ostomisticHi and welcome to Chemo Diaries: My expe...
-
Young Adult Cancer ConnectionYoung Adult Cancer Connection, co-founde...
-
Charité – Universitätsmedizin BerlinThe center offers care to patients at ri...